Algenpantucel-L, an allogeneic PC vaccine composed of two human PDAC cell lines (HAPa-1 and HAPa-2) that have been genetically engineered to express αGal by using retroviral transfer of the murine αGT gene, was tested in addition to chemotherapy and chemoradiotherapy as an adjuvant treatment in 70 patients with resected PC [122]. This evidence concerns the gene AGT and pachyonychia congenita.